Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

J Microbiol Immunol Infect. 2017 Aug;50(4):541-544. doi: 10.1016/j.jmii.2016.11.006. Epub 2017 Jun 26.

Abstract

We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4-40.6). Results confirm intravenous peramivir's usefulness.

Keywords: Aging; Antiviral drugs; Geriatrics; Gerontology; High-risk patient; Neuraminidase inhibitor.

MeSH terms

  • Acids, Carbocyclic
  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects*
  • Cyclopentanes / administration & dosage*
  • Cyclopentanes / adverse effects*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Female
  • Guanidines / administration & dosage*
  • Guanidines / adverse effects*
  • Humans
  • Influenza, Human / drug therapy*
  • Male
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Acids, Carbocyclic
  • Antiviral Agents
  • Cyclopentanes
  • Guanidines
  • peramivir